This review summarizes the indications, updated prothrombin time targets, and significant risks associated with warfarin therapy.
Answers are grounded in this paper and cite their sources.
Highlights need for vigilant warfarin monitoring; leaves open optimal targets in contemporary cohorts.
Oral anticoagulants are used extensively, although their risks are not always fully recognized. The prophylaxis of venous thrombosis after hip surgery, the prevention of deep venous thrombosis and pulmonary emboli after an acute episode of these, the prevention of arterial emboli from the heart in patients at risk, and the prophylaxis of thrombosis in patients with congenital deficiency of antithrombin III, protein C, or protein S are some of the indications for oral anticoagulant use. Warfarin sodium is contraindicated in pregnancy, however. The recommended prothrombin time is 1 1/2 to two times control, lower than previously. The major risk of oral anticoagulant therapy, bleeding, is treated with vitamin K or plasma, depending on its severity. Warfarin necrosis and the "purple-toe" syndrome are seen more frequently than realized.
No takes yet. Share an insight, caveat, or question.
C. E. Peterson (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: